What is the intramuscular (IM) dose of midazolam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended intramuscular (IM) dose of midazolam is 5-10 mg for adults and 0.1 mg/kg for children, with a maximum dose of 10 mg. When considering the administration of midazolam, it is crucial to take into account the patient's age and the specific clinical indication. For adults, the typical dose ranges, but a common dose is between 5-10 mg, as indicated in the study 1. The dose for children is typically 0.1 mg/kg, which can be found in the same study 1. It's also important to note that the dose may be repeated every 20-30 minutes as needed, but this should be done with caution and close monitoring of the patient's response and potential side effects. The study 1 provides guidance on the dose and administration of midazolam, including the recommendation to repeat the dose every 20-30 minutes if necessary. Some key points to consider when administering midazolam include:

  • The dose should be individualized based on the patient's response and medical history
  • The patient should be closely monitored for signs of respiratory depression and other potential side effects
  • The use of midazolam should be avoided or used with caution in patients with a history of substance abuse or those who are taking other central nervous system depressants. As stated in the study 1, the maximum daily dose is 40 mg for adults and 30 mg for children, and this should not be exceeded. It's also worth noting that midazolam can be administered via different routes, including orally and intravenously, but the IM route is commonly used for its convenience and rapid onset of action. Overall, the key to safe and effective use of midazolam is careful patient selection, individualized dosing, and close monitoring for potential side effects, as recommended in the study 1.

From the FDA Drug Label

For preoperative sedation/anxiolysis/amnesia (induction of sleepiness or drowsiness and relief of apprehension and to impair memory of perioperative events). For intramuscular use, midazolam hydrochloride should be injected deep in a large muscle mass The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0. 08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The recommended IM dose of midazolam is:

  • 0.07 to 0.08 mg/kg for adult patients below 60 years
  • Approximately 5 mg IM for good risk adult patients
  • 2 to 3 mg (0.02 to 0.05 mg/kg) for patients 60 years or older who did not receive concomitant administration of narcotics 2

From the Research

Intramuscular Dose of Midazolam

The intramuscular (IM) dose of midazolam is an important consideration for various medical applications, including sedation and the treatment of status epilepticus.

  • The recommended IM dose of midazolam can vary depending on the specific application and patient population 3, 4.
  • A study published in 1989 suggested that a dose of 0.05 mg/kg is sufficient for sedation, and higher doses may increase the risk of unconsciousness 3.
  • Guidelines recommend 10-mg IM midazolam as the first-line treatment option for status epilepticus 4.
  • However, in real-world practice, lower doses are often used, and the effectiveness of midazolam can depend on the route of administration and dose used 4.

Comparison of Routes of Administration

Different routes of administration, including IM, intravenous (IV), and intranasal (IN), have been compared in terms of their effectiveness for treating seizures and status epilepticus.

  • A study published in 2022 found that IN midazolam increased the risk of rescue therapy, while IV midazolam decreased this risk compared to IM administration 4.
  • Another study published in 2015 found that parenteral midazolam was superior to diazepam for treating prehospital seizures, with a higher success rate for first-dose seizure suppression 5.

Pharmacokinetics and Pharmacodynamics

The pharmacokinetics and pharmacodynamics of midazolam are important factors to consider when determining the optimal dose and route of administration.

  • Midazolam has a rapid onset of action and a relatively short half-life, making it a useful agent for sedation and seizure treatment 6, 3.
  • The drug is metabolized by the cytochrome P450 enzyme system, and its metabolism can be affected by inhibitors such as cimetidine 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.